Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silymarin solution for prevention of radiotherapy-induced mucositis in head and neck cancer
IRCT20241014063364N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of silymarin in head and neck cancer (HNC) and stomatitis, sponsored by Shiraz University of Medical Sciences. Primary endpoint: Prevention of radiotherapy-induced mucositis. Started Sep 2024; status: completed.
02
Drugs
silymarin
03
Conditions
head and neck cancer (HNC)stomatitis
Beyond the preview
Go deeper on IRCT20241014063364N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241014063364N1.